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{{BACKGROUND Cardiac biomarker release signifying myocardial injury post-transcatheter aortic valve replacement
(TAVR) is common, yet its clinical impact within a large TAVR cohort receiving differing types of valve and procedural
approaches is unknown.
OBJECTIVES This study sought to determine the incidence, clinical impact, and factors associated with cardiac
biomarker elevation post TAVR.
METHODS This multicenter study included 1,131 consecutive patients undergoing TAVR with balloon-expandable (58%)
or self-expandable (42%) valves. Transfemoral and transapical (TA) approaches were selected in 73.1% and 20.3% of
patients, respectively. Creatine kinase-myocardial band (CK-MB) measurements were obtained at baseline and at several
time points within the initial 72 h post TAVR. Echocardiography was performed at baseline and at 6- to 12-month follow-
up.
RESULTS Overall, 66% of the TAVR population demonstrated some degree of myocardial injury as determined by a rise
in CK-MB levels (peak value: 1.6-fold [interquartile range (IQR): 0.9 to 2.8-fold]). A TA approach and major procedural
complications were independently associated with higher peak of CK-MB levels (p < 0.01 for all), which translated into
impaired systolic left ventricular function at 6 to 12 months post TAVR (p < 0.01). A greater rise in CK-MB levels
independently associated with an increased 30-day, late (median of 21 [IQR: 8 to 36] months) overall and cardiovascular
mortality (p < 0.001 for all). Any increase in CK-MB levels was associated with poorer clinical outcomes, and there was a
stepwise rise in late mortality according to the various degrees of CK-MB increase after TAVR (p < 0.001).
CONCLUSIONS Some degree of myocardial injury was detected in two-thirds of patients post TAVR, especially in
those undergoing TA-TAVR or presenting with major procedural complications. A greater rise in CK-MB levels asso-
ciated with greater acute and late mortality, imparting a negative impact on left ventricular function.
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2076T ranscatheter aortic valve replace-ment (TAVR) has emerged as a ther-apeutic alternative to surgical aortic
valve replacement (SAVR) for patients with
severe aortic stenosis (AS) at high or pro-
hibitive perioperative risk (1). Compared
with conventional open-heart surgery, TAVR
procedures are less invasive due to the
avoidance of aortic cross-clamping and car-
dioplegia. However, TAVR systematically
associates with some degree of myocardial
injury, deﬁned biochemically by variable in-
creases in cardiac biomarkers (2–4). A nega-
tive clinical impact associated with a higherdegree of myocardial injury post TAVR has also been
suggested (2,5), and the recent Valve Academic
Research Consortium (VARC-2) consensus on TAVR
has established speciﬁc biomarkers cut-off values
for deﬁning clinically signiﬁcant myocardial infarc-
tion post TAVR (2,6). However, a validation of these
VARC deﬁnitions upon clinically relevant myocardial
infarction post TAVR is still lacking.SEE PAGE 2089Prior studies evaluating myocardial injury post
TAVR included limited numbers of patients and
duration of follow-up, with a paucity of cardiovascu-
lar outcomes data (2–4). Also, a single transcatheter
valve system (balloon- or self-expandable) and/or
delivery approach were used in most previous studies
(2–4). Thus, a comprehensive understanding of the
factors associated with myocardial injury post TAVR
in a real-world all-comers population, incorporating
the true clinical impact of varying degrees of myo-
cardial injury detected biochemically, is currently
lacking. Finally, most previous studies had focused on
troponin levels as a biomarker of myocardial injury,
yet there are limited data regarding the impact
of creatinine kinase-myocardial band (CK-MB)
levels, which has undergone a more robust validation
for deﬁning periprocedural myocardial infarction
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received April 27, 2015; revised manuscript received August 21,intervention ﬁelds (7). The objectives of the present
study were to evaluate the incidence, prognostic sig-
niﬁcance and factors associated with myocardial
injury as determined by CK-MB elevation (including
validation of the VARC-2 proposed cut-off for myo-
cardial infarction) in a large multicenter cohort of
patients undergoing TAVR with differing valve types
and approaches.
METHODS
STUDY POPULATION. This was a multicenter study
including 1,172 patients who underwent TAVR from
March 2007 until December 2014, in different centers
across North America, South America, and Europe.
A total of 41 patients were excluded due to
procedural death (within the ﬁrst 24 h after the
procedure), precluding the collection of at least one
blood sample for cardiac biomarker measurements
post procedure. Therefore, the ﬁnal study popula-
tion consisted of 1,131 patients, 486 patients (43.0%)
from 3 centers in North America, 123 patients (10.9%)
from 4 centers in South America and 522 pa-
tients (46.1%) from 6 centers in Europe. A balloon-
expandable valve was used in 658 patients, being an
Edwards-Sapien (Edwards Lifesciences Inc., Irvine,
California) in 261 (23.1%), Sapien XT (Edwards Life-
sciences Inc.) in 380 (33.6%), Sapien 3 (Edwards
Lifesciences Inc.) in 14 (1.2%), and Inovare (Braile
Biomedical, São Paulo, Brazil) in 2 patients (0.2%).
Also, a self-expandable valve was used in 473 pa-
tients, being a CoreValve (Medtronic, Minneapolis,
Minnesota) in 458 (40.5%), Portico (St. Jude Medical,
Minneapolis, Minnesota) in 13 (1.1%), and Lotus
(Boston Scientiﬁc SciMed Inc., Maple Grove, Minne-
sota) in 1 (0.1%). Indications for TAVR, device type
and approach were based on the assessment
recommendation of the heart team at each center.
Data were prospectively collected in a dedicated
database at each center. The ﬁrst one-half of pa-
tients treated at each center were considered as
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TABLE 1 Clinical, Echocardiographic, and Procedural Characteristics of the
Study Population (N ¼ 1,131)
Clinical variables
Age, yrs 80  7
Male 572/1,131 (50.6)
NYHA functional class
I-II 266/1,123 (23.7)
III-IV 857/1,123 (76.3)
Coronary artery disease 608/1,131 (53.8)
Prior PCI 346/1,130 (30.6)
Prior CABG 253/1,131 (22.4)
History of atrial ﬁbrillation 307/1,080 (28.4)
Cerebrovascular disease 142/880 (16.1)
Peripheral vascular disease 264/1,131 (23.3)
COPD 304/1,131 (26.9)
Porcelain aorta 153/1,131 (13.5)
eGFR, ml/min/1.73 m2 60.7  25.5
CKD 608/1,130 (53.8)
STS-PROM, % 8.2  6.8
Echocardiographic variables
LVEF, % 56  15
Mean aortic gradient, mm Hg 45.6  16.8
Aortic valve area, cm2 0.64  0.22
Moderate/severe mitral regurgitation 212/924 (22.9)
Procedural variables
Success* 879/1,116 (78.8)
Approach
Transfemoral 827/1,131 (73.1)
Transapical 230/1,131 (20.3)
Transaortic 48/1,131 (4.3)
Subclavian 26/1,131 (2.3)
Prosthesis type
Balloon-expandable 658/1,131 (58.2)
Self-expandable 473/1,131 (41.8)
Prosthesis size, mm
#26 830/1,122 (74.0)
>26 292/1,122 (26.0)
Valve-in-valve 61/1,131 (5.4)
Time of procedure “skin to skin,” min 70 (60–88)
30-day outcomes
Major vascular complications 136/1,130 (12.0)
Major or life-threatening bleeding 140/1,129 (12.4)
Valve embolization/need for a second valve 57/1,131 (5.0)
Pacemaker 173/1,130 (15.3)
Coronary obstruction 6/1,131 (0.5)
Stroke 40/1,131 (3.5)
Death 65/1,131 (5.7)
Hospitalization length, days 7 (5–12)
Echocardiographic post procedure
LVEF, % 57  14
Mean aortic gradient, mm Hg 10.8  6.0
Aortic valve area, cm2 1.56  0.50
Moderate/severe mitral regurgitation 111/744 (14.9)
Moderate/severe aortic regurgitation 132/1,101 (12.0)
Values are mean  SD, n/N (%), or median (interquartile range). *Following Valve Academic
Research Consortium-2 criteria (6).
CABG ¼ coronary artery bypass graft; CKD ¼ chronic kidney disease; COPD ¼ chronic
obstructive pulmonary disease; eGFR ¼ estimated glomerular ﬁltration; LVEF ¼ left ventricular
ejection fraction; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention;
STS-PROM ¼ Society of Thoracic Surgeons predicted risk of mortality.
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Valve Academic Research Consortium (VARC)-2
criteria (6). Clinical follow-up was carried out by
clinical visits and/or through phone contact at 1
month, 6-months to 12-months post TAVR, and
yearly thereafter in all participating centers. Com-
plete clinical follow-up was available in all but 6
patients, lost to follow-up (0.5%).
MEASUREMENTS OF SERUM MARKERS SIGNIFYING
MYOCARDIAL INJURY. Blood samples were collected
at baseline, and at 6 to 12, 24, 48, and 72 h post TAVR,
with CK-MB levels being measured at each time point.
The upper normal limits for CK-MB were established
at each participating institution based on the 99th
percentile values in a healthy population. Myocardial
injury was deﬁned as an increase in CK-MB above this
upper limit at any time point (up to 72 h) post TAVR.
The degree of CK-MB elevation was calculated by
dividing the CK-MB level by the upper limit level, and
this was expressed as n-fold increase. In those pa-
tients with elevated baseline CK-MB levels, myocar-
dial injury was deﬁned as any increase >20% post
procedure (8).
DOPPLER-ECHOCARDIOGRAPHIC MEASUREMENTS. A
Doppler echocardiographic examination was per-
formed at baseline, pre-TAVR, upon hospital
discharge and at 6 months to 1 year post TAVR.
Echocardiographic data at follow-up was available in
532 patients (62.7% of the study population at risk).
The following measurements were obtained in all
patients: aortic annulus diameter, left ventricular
ejection fraction (LVEF) (calculated by the biplane
Simpson method), mean transvalvular gradient
(calculated with the Bernoulli formula), and the valve
effective oriﬁce area (AVA; calculated by the conti-
nuity equation). The presence and severity of aortic
regurgitation was recorded in all patients. Severity of
aortic regurgitation was classiﬁed according to the
VARC-2 classiﬁcation as follows: none/trace, mild,
moderate, and severe (6).
STATISTICAL ANALYSIS. Categorical variables are
reported as n (%). Continuous variables are expressed
as mean  SD or median (25th to 75th interquartile
range [IQR]), depending upon variable distribution.
Group comparisons were performed using the Stu-
dent t test or Wilcoxon rank sum test for continuous
variables and chi-square test for categorical variables.
For CK-MB analysis the values after the procedure
were evaluated in relation to the upper limit as
determined at each center. Two experimental factors
(subjects classiﬁed as random factor and time period
as a ﬁxed factor) were deﬁned to analyze the
changes in repeated CK-MB measurements over time
FIGURE 1 Changes in Serum Markers of Myocardial Injury After TAVR
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Changes in CK-MB levels within 72 h after TAVR in the entire study population (A) and
grouped according to the approach (TA vs. non-TA) (B). Values are expressed as median
(25th to 75th interquartile range). CK-MB ¼ creatine kinase-myocardial band; TA ¼
transapical; TAVR ¼ transcatheter aortic valve replacement.
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2078(baseline, 6 to 12, 24, 48, and 72 h). Considering the
presence of some missing CK-MB measurements in
11% of patients, the CK-MB levels over time were
analyzed as a repeated-measures factor with the use
of an unstructured covariance matrix to obtain unbi-
ased estimates. Ulterior comparisons were performed
using the Tukey method. The normality assumption
was veriﬁed with the Shapiro-Wilk tests on the error
distribution from the Cholesky factorization of the
statistical model. The Brown and Forsythe variation
of Levene’s test statistic was used to verify the ho-
mogeneity of variances. CK-MB elevation values were
log transformed to stabilize variances. Reported
p-values were based on this transformation. The pre-
dictors of higher rise in CK-MB values weredetermined using a linear regression analyses
normalized by baseline values. Univariate and multi-
variate logistic regression analyses were used to
determine the predictors of 30-day mortality.
Continuous variables were checked for the assump-
tion of linearity using quartiles of the distribution and
fractional polynomials before building the model in
order to obtain the correct relationships. The graphic
representations suggested linear relationships with
the logit for all continuous variables. Univariate and
multivariate Cox proportional hazard models were
used to determine the predictors of cumulative late
overall and cardiac mortality. Variables with a prob-
ability value <0.10 were candidates for the multi-
variate regression model building. Coronary artery
disease was also added into the multivariate models.
The ﬁnal statistical model was built using 2 statistical
approaches: a forward approach, Akaike and Schwarz’
Bayesian criteria. For the Cox models, the martingales
residuals were used to examine the functional form of
the continuous variables. Measurements of CK-MB
elevation were log-transformed. After model build-
ing, the adequacy of the proportional hazards
assumption was checked. To check the proportional-
ity assumption, we ﬁrst used the graphical represen-
tation of the logarithm cumulative hazard rates
versus time to assess parallelism and the constant
separation among the different values of nominal
variables, whereas the continuous variables were
stratiﬁed into 4 strata. Second, an artiﬁcially time-
dependent covariate was added to the model to test
the proportionality assumption. For all variables in
the ﬁnal models, the proportional hazards assump-
tions were not rejected as local tests linked to the
time-dependent covariates were not signiﬁcant and
scatter plots were roughly constant over time. All
analyses were performed using a hierarchical method
in order to account for between-center variability.
Mortality rates were presented using Kaplan-Meier
estimates and comparisons between groups were
performed using the log-rank test. The correlation
between LVEF and CK-MB increase were evaluated
with the Pearson’s correlation. All results were
considered signiﬁcant with p values <0.05. Analyses
were conducted using the statistical packages SAS,
version 9.4 (SAS Institute Inc., Cary, North Carolina)
and Statistical Package for Social Sciences, version 20
(SPSS Inc., IBM, Armonk, New York).
RESULTS
The clinical, echocardiographic, procedural charac-
teristics and 30-day outcomes of the study popula-
tion are shown in Table 1. Also, the clinical,
FIGURE 2 Degree of Increase in CK-MB Levels After TAVR
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2079echocardiographic, and procedural characteristics
and 30-day outcomes of the study population ac-
cording to valve type are shown in Online Table 1.
SERUM MARKERS OF MYOCARDIAL INJURY POST-TAVR.
The median peak values of CK-MB at each time point
within the initial 72 h post TAVR, overall and strat-
iﬁed according to the approach (TA vs. non-TA) are
shown in Figure 1. CK-MB levels were within normal
limits in 92.0% of the patients at baseline and rose
above the upper normal limit in 65.6% of patients,
with a median increase of 1.6-fold (IQR: 0.9- to
2.8-fold) at 12 to 24 h post TAVR, and returned to
baseline values at 72 h post TAVR. In the TA cohort,
CK-MB levels rose above the upper normal values in
97.3% of patients compared with 54.4% of patients in
the non-TA (TF, transaortic and trans-subclavian)
cohort (p < 0.001), with median peak values of 2.2-
fold (IQR: 1.6- to 3.3-fold) and 1.2-fold (IQR: 0.7- to
2.4-fold), respectively (p < 0.001). The percent of
patients with increased CK-MB levels grouped ac-
cording to the degree of rise in CK-MB post TAVR in
the entire study population and to the approach are
shown in Figure 2.
PREDICTORS OF MYOCARDIAL INJURY POST-TAVR. The
degree of myocardial injury according to baseline and
procedural characteristics of the entire study popu-
lation is shown in Table 2. Factors associated with a
greater degree of myocardial injury in the multivar-
iate analysis were a TA approach (R2: 0.070;
p < 0.001), an early TAVR experience (R2: 0.013;
p < 0.001) and procedural complications such as
valve embolization/need for a second valve (R2: 0.019;
p < 0.001), major/life-threatening bleeding (R2: 0.007;
p ¼ 0.001), and conversion to open-heart surgery
(R2: 0.013; p < 0.001). The degree of myocardial injury
according to baseline and procedural characteristics
for the non-TA cohort is shown in Table 3. Factors
associated with a greater degree of myocardial injury
in the multivariate analysis (non-TA cohort) were the
use of a self-expandable valve (R2: 0.039; p < 0.001),
valve embolization/need for a second valve (R2: 0.007;
p¼0.009), major/life-threatening bleeding (R2: 0.009;
p ¼ 0.003), conversion to open-heart surgery (R2:
0.022; p<0.001) and early TAVR experience (R2: 0.011;
p ¼ 0.001). The results were similar when only the
CoreValve system was evaluated in the self-
expandable valve group (Online Table 2).
In an additional analysis, the factors associated
with an increase in CK-MB levels >5-fold were also
evaluated. The baseline and procedural characteris-
tics of patients according to a CK-MB increase >5-fold
are shown in Online Table 3. The results of the uni-
variate and multivariate analyses for determining thepredictors of a CK-MB rise >5-fold in the entire study
population and the non-TA cohort are shown in
Online Table 4. The TA approach, valve embolization/
need for a second valve and conversion to open-heart
surgery were the independent predictors of a rise in
CK-MB >5-fold post TAVI (p < 0.05 for all).
CLINICAL IMPACT OF MYOCARDIAL INJURY. A total
of 65 patients (5.7%) had died at 30 days post TAVR,
and a further 328 patients died (29.0%) at a median
follow-up of 21 (8 to 36) months post TAVR. A total of
191 patients died from cardiac causes (16.9%, 58.2% of
the deaths). The variables associated with a higher
risk of 30-day mortality, cumulative late overall and
cardiac mortality are shown in Table 4. A greater in-
crease in CK-MB levels was associated with increased
30-day mortality (OR: 2.26 for each increase of 1-fold
above upper limit values; 95% CI: 1.76 to 2.90;
p < 0.001), and remained independently associated
with greater 30-day mortality in the multivariate
analysis (OR: 1.71; 95% CI: 1.25 to 2.35; p < 0.001).
Greater increments in CK-MB levels post TAVR were
also independently associated with late cumulative
mortality (HR: 1.32 for each increase of 1-fold increase
above the upper limit values; 95% CI: 1.12 to 1.54;
p < 0.001) and late cardiac mortality (HR: 1.39; 95%
CI: 1.12 to 1.74; p ¼ 0.003). In a subanalysis of the TF
and TA cohorts, a greater increase in CK-MB levels
remained as an independent predictor of 30-day
and late mortality in the TF cohort (p < 0.001 for
both) (Online Table 5), but not in the TA cohort
(Online Table 6).
TABLE 2 Overall Degree of CK-MB Increase After TAVR
According to Baseline and Procedural Variables (N ¼ 1,131)
CK-MB Fold p Value
Baseline variables
Age, yrs
$ Median (82 yrs) 1.58 (0.85–2.71) 0.242
< Median (82 yrs) 1.44 (0.81–2.60)
Sex
Male 1.51 (0.85–2.64) 0.783
Female 1.50 (0.80–2.73)
History of atrial ﬁbrillation/ﬂutter
Yes 1.36 (0.72–2.36) 0.371
No 1.50 (0.85–2.65)
Coronary artery disease
Yes 1.52 (0.86–2.69) 0.549
No 1.47 (0.80–2.66)
Prior CABG
Yes 1.58 (0.89–2.47) 0.599
No 1.47 (0.82–2.69)
Prior PCI
Yes 1.52 (0.87–2.68) 0.583
No 1.50 (0.82–2.66)
Cerebrovascular disease
Yes 1.60 (0.85–2.95) 0.246
No 1.53 (0.83–2.70)
Peripheral vascular disease
Yes 1.75 (1.11–2.78) <0.001
No 1.39 (0.79–2.67)
COPD
Yes 1.50 (0.88–2.61) 0.701
No 1.50 (0.82–2.69)
eGFR, ml/min/1.73 m2
$ Median (60 ml/min) 1.49 (0.82–2.67) 0.471
< Median (60ml/min) 1.51 (0.84–2.67)
STS-PROM
$ Median (6%) 1.53 (0.88–2.51) 0.105
< Median (6%) 1.47 (0.82–2.78)
Porcelain aorta
Yes 1.74 (1.08–2.82) 0.027
No 1.44 (0.80–2.64)
Continued in the next column
TABLE 2 Continued
CK-MB Fold p Value
Procedural variables
Prosthesis type
Balloon–expandable 1.53 (0.80–2.65) 0.015
Self-expandable 1.44 (0.87–2.69)
Approach
Transfemoral/transaortic/
trans-subclavian
1.20 (0.73–2.35) <0.001
Transapical 2.20 (1.63–3.34)
Device success
Yes 1.50 (0.83–2.63) 0.029
No 1.52 (0.89–2.85)
Life-threatening/major bleeding
Yes 2.27 (1.16–3.83) <0.001
No 1.41 (0.79–2.44)
Major vascular complications
Yes 1.82 (0.95–3.24) 0.001
No 1.46 (0.81–2.60)
Valve embolization/need for
a second valve
Yes 2.39 (1.19–6.44) <0.001
No 1.48 (0.82–2.60)
Conversion to surgery
Yes 4.65 (1.64–7.76) <0.001
No 1.48 (0.82–2.64)
Coronary obstruction
Yes 7.46 (3.27–9.02) <0.001
No 1.50 (0.83–2.64)
TAVR experience
Early 1.81 (0.98–3.19) <0.001
Late 1.19 (0.72–2.16)
CK-MB ¼ creatinine kinase-myocardial band; TAVR ¼ transcatheter aortic valve
replacement; other abbreviations as in Table 1.
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according to differing degrees of CK-MB increments
(<1-, 1- to 3-, 3- to 5-, and >5-fold) are shown in
Figures 3 and 4, for the overall and non-TA cohorts,
respectively. Any increase in CK-MB levels (<1-fold
vs. >1-fold) was associated with a higher mortality
(p < 0.001), and there was a stepwise increase in late
mortality according to the various degrees of CK-MB
elevation after TAVR (p < 0.001). In those patients
with increased CK-MB levels, a >5-fold increase was
associated with a higher overall (33.6% vs. 22.9% at
2 years; p < 0.001), and cardiac mortality (25.8% vs.
14.1%; p < 0.001). In the non-TA cohort, a >5-fold
increase in CK-MB levels was also associated with
increased overall (30.6% vs. 20.1%; p < 0.001) and
cardiac mortality (24.6% vs. 12.1%; p < 0.001).The correlation between the increase in CK-MB
levels and the changes in LVEF between baseline
and follow-up (D) for the entire population are
shown in Figure 5. The increase in CK-MB levels
after the procedure demonstrated a weak, but sig-
niﬁcant negative impact in changes of LVEF
between baseline and follow-up (r ¼ -0.17; p < 0.001).
Also, the patients presenting with either unchanged
or reduced LVEF 6-12 months post TAVR compared
to baseline exhibited greater CK-MB levels as com-
pared with those patients whose LVEF signiﬁcantly
improved after TAVR (p ¼ 0.004; Figure 6).
DISCUSSION
The present large-scale real-world study demon-
strates that some degree of myocardial injury, as
determined by a post-procedural rise in CK-MB
levels, is common after TAVR. The use of the TA
TABLE 3 Overall Degree of CK-MB Increase After
TAVR in the Nontransapical Cohort (Transfemoral, Transaortic,
and Trans-Subclavian) According to the Baseline and
Procedural Variables
CK-MB Fold p Value
Baseline variables
Age, yrs
$ Median (82 yrs) 1.21 (0.73–2.36) 0.713
< Median (82 yrs) 1.19 (0.73–2.35)
Sex
Male 1.19 (0.73–2.40) 0.607
Female 1.22 (0.73–2.27)
History of atrial
ﬁbrillation/ﬂutter
Yes 1.04 (0.64–1.94) 0.113
No 1.25 (0.75–2.29)
Coronary artery disease
Yes 1.17 (0.72–2.37) 0.978
No 1.27 (0.75–2.34)
Prior CABG
Yes 1.11 (0.67–2.29) 0.923
No 1.25 (0.75–2.36)
Prior PCI
Yes 1.19 (0.72–2.27) 0.540
No 1.22 (0.73–2.37)
Cerebrovascular disease
Yes 1.19 (0.70–2.29) 0.819
No 1.13 (0.70–2.36)
Peripheral vascular disease
Yes 1.28 (0.73–2.27) 0.215
No 1.19 (0.73–2.36)
COPD
Yes 1.16 (0.72–2.09) 0.265
No 1.24 (0.73–2.39)
eGFR, ml/min/1.73 m2
$ Median (60 ml/min) 1.17 (0.75–2.37) 0.635
< Median (60ml/min) 1.25 (0.69–2.34)
STS-PROM
$ Median (6%) 1.15 (0.69–2.11) 0.051
< Median (6%) 1.25 (0.75–2.45)
Porcelain aorta
Yes 1.19 (0.75–1.94) 0.363
No 1.20 (0.73–2.37)
Continued in the next column
TABLE 3 Continued
CK-MB Fold p Value
Procedural variables
Prosthesis type
Balloon–expandable 0.99 (0.65–1.97) <0.001
Self-expandable 1.42 (0.86–2.69)
Device success
Yes 1.19 (0.73–2.29) 0.039
No 1.33 (0.74–2.66)
Life-threatening/major bleeding
Yes 2.00 (0.94–3.60) <0.001
No 1.17 (0.70–2.20)
Major vascular complications
Yes 1.68 (0.90–2.98) <0.001
No 1.17 (0.70–2.25)
Valve embolization/need
for a second valve
Yes 1.62 (1.04–6.45) <0.001
No 1.19 (0.72–2.28)
Conversion to surgery
Yes 4.41 (1.53–7.28) <0.001
No 1.19 (0.73–2.29)
Coronary obstruction
Yes 5.37 (3.09–28.6) <0.001
No 1.19 (0.73–2.32)
TAVR experience
Early 1.39 (0.81–2.86) <0.001
Late 1.10 (0.68–1.98)
Abbreviations as in Tables 1 and 2.
J A C C V O L . 6 6 , N O . 1 9 , 2 0 1 5 Ribeiro et al.
N O V E M B E R 1 0 , 2 0 1 5 : 2 0 7 5 – 8 8 Myocardial Injury Post-TAVR
2081approach and major procedural complications such as
valve embolization/need for a second valve, major/
life-threatening bleeding and conversion to open-
heart surgery were the most important factors asso-
ciated with a larger increase in CK-MB levels. Greater
degree of myocardial injury was independently
associated with poorer outcomes as determined by an
increase in 30-day and late mortality, as well as
impaired LVEF at 6- to 12-month follow-up. Any in-
crease in CK-MB levels after TAVR was associated
with poorer clinical outcomes, with a stepwise in-
crease in mortality according to the various degrees of
CK-MB elevation (Central Illustration).INCIDENCE AND DEGREE OF MYOCARDIAL INJURY
POST TAVR. Most patients undergoing SAVR expe-
rience some degree of myocardial injury, reﬂected
by rise in CK-MB levels, and a >5-fold increase in
the upper normal limits occurs in nearly 20% of
these patients (9,10). While avoiding the need for
cardiopulmonary bypass translates into a lesser de-
gree of myocardial injury during TAVR, up to two-
thirds of patients undergoing TAVR had signiﬁcant
elevation in CK-MB levels post procedure, and the
frequency of >3-fold and $5-fold increases in
CK-MB upper normal limits occurred in 21.0% and
9.6% of cases, respectively. These ﬁndings appear
similar to those observed during percutaneous cor-
onary intervention (11).
In accordance with previous smaller studies, a TA
approach was found to be one of the most important
factors in determining a higher degree of myocardial
injury post TAVR in the present study (2,4). TA-TAVR
involves puncturing and introducing a large bore
catheter through the LV apex, and this has been
postulated as the primary reason for biomarker ele-
vations in such instances (2,12). Additionally, this has
been related to new myocardial necrosis as evaluated
by cardiac magnetic resonance, involving w5% of the
TABLE 4 Univariate and Multivariate Analyses of the Predictor of Poorer Outcomes Post-TAVR
Outcome
Univariate
p Value
Multivariate Model
p ValueOR/HR (95% CI) OR/HR (95% CI)
30-day mortality (n ¼ 65)
Coronary artery disease 0.75 (0.45–1.25) 0.275 – –
Peripheral vascular disease 1.84 (1.04–3.26) 0.035 – –
LVEF 0.98 (0.97–0.99) 0.041 0.98 (0.96-0.99) 0.026
Early experience 1.99 (1.17–3.38) 0.011 – –
Major or life-threatening bleeding 5.83 (3.38–10.04) <0.001 3.07 (1.57–5.99) 0.001
Stroke 3.97 (1.64–9.60) 0.002 – –
Acute kidney injury 10.01 (5.66–17.7) <0.001 6.11 (3.32–11.22) <0.001
CK-MB elevation* 2.26 (1.76–2.90) <0.001 1.71 (1.25–2.35) <0.001
Cumulative mortality (n ¼ 328)
Male 1.27 (1.02–1.60) 0.036 – –
NYHA functional class III-IV 1.92 (1.40–2.64) <0.001 1.85 (1.29–2.66) <0.001
History of atrial ﬁbrillation 1.82 (1.44–2.30) <0.001 1.69 (1.30–2.20) <0.001
Coronary artery disease 1.18 (0.94–1.48) 0.157 – –
Cerebrovascular disease 1.36 (1.02–1.82) 0.035 – –
Peripheral vascular disease 1.46 (1.13–1.90) 0.004 – –
COPD 1.52 (1.20–1.93) <0.001 1.42 (1.08–1.87) 0.01
TA approach 1.57 (1.15–2.15) 0.005 – –
Early experience 1.29 (0.98–1.69) 0.060 – –
Life-threatening/major bleeding 2.01 (1.54–2.64) <0.001 – –
Stroke 2.05 (1.30–3.23) 0.002 – –
Acute kidney injury 2.67 (2.09–3.42) <0.001 2.12 (1.60–2.80) <0.001
CK-MB elevation* 1.42 (1.26–1.62) <0.001 1.32 (1.12–1.54) <0.001
Cumulative cardiac mortality (n ¼ 191)
Male 1.36 (1.01–1.83) 0.042 – –
NYHA functional class III-IV 1.73 (1.16–2.60) 0.008 – –
History of atrial ﬁbrillation 1.62 (1.18–2.21) 0.003 – –
Coronary artery disease 0.99 (0.74–1.33) 0.959 – –
Peripheral vascular disease 1.55 (1.11–2.15) 0.009 – –
COPD 1.54 (1.13–2.09) 0.006 1.68 (1.15–2.45) 0.007
LVEF 0.99 (0.98–0.99) 0.022 0.99 (0.98–0.99) 0.039
Moderate/Severe mitral regurgitation 1.56 (1.07–2.27) 0.022 – –
TA approach 1.81 (1.20–2.71) 0.004 – –
Early experience 1.48 (1.05–2.08) 0.024
Life-threatening/major bleeding 2.29 (1.62–3.22) <0.001 1.75 (1.14–2.69) 0.010
Stroke 2.79 (1.64–4.75) <0.001 – –
Acute kidney injury 3.73 (2.74–5.07) <0.001 3.06 (2.07–4.52) <0.001
CK-MB elevation* 1.60 (1.37–1.87) <0.001 1.39 (1.12–1.74) 0.003
*For every 1-fold increase of CK-MB level in relation to the upper limit.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; OR ¼ odds ratio; TA ¼ transapical; other abbreviations as in Tables 1 and 2.
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2082myocardium at the apex (12), leading to apical wall
abnormalities (5,12,13). Several studies have found
the TA approach to be independently associated with
mortality (14,15), and a recent study identiﬁed that
this approach correlates with late mortality secondary
to advanced heart failure (16). The results of this
study highlight the importance of myocardial injury
as the potential pathophysiological link between
TA approach and increased mortality, outlining the
importance of minimizing myocardial damage in such
cases (i.e., reducing sheath size or avoiding myocar-
dial tears).Major periprocedural complications such as major/
life-threatening bleeding, valve embolization/need
for a second valve and conversion to open-heart
surgery were also associated with a greater increase
in CK-MB levels. Previous studies have shown the
negative clinical impact of these complications after
TAVR (17,18). The present study suggests that an as-
sociation with a higher degree of myocardial injury
may further contribute to poorer outcomes in such
patients. While the link between open-heart surgery
and myocardial injury is obvious, one may hypothe-
size that periods of severe hypotension, longer
FIGURE 3 Kaplan-Meier Mortality Curves in All Patients
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Kaplan-Meier mortality curves for cumulative overall death (A) and for cardiovascular death (B) according to the percentiles of CK-MB peak of
increase after TAVR. For group comparisons in (A) group <1 versus groups 1 to 3, 3 to 5, and >5 (p < 0.05); in (B) group 1 versus groups 1 to 3, 3
to 5, and >5 (p < 0.01). Abbreviations as in Figure 1.
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2083procedures with increased ischemic times
and increased device manipulation may have con-
tributed to the increased levels of CK-MB levels in
patients suffering from major bleeding or devicemalpositioning/embolization. An early stage in the
TAVR experience was also associated with a greater
CK-MB increase, suggesting both the roles of the
learning curve and the advancements in the TAVR
FIGURE 4 Kaplan-Meier Survival Curves in Non-TA Patients
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2084technology on the degree of myocardial injury post
TAVR.
Apart from major periprocedural complications,
the use of a self-expandable valve was also associatedwith a mild but signiﬁcant higher rise in CK-MB levels
in the non-TA cohort. Similar to the results reported
in the CHOICE (Comparison of Balloon-Expandable
vs Self-expandable Valves in Patients Undergoing
FIGURE 5 Myocardial Injury and LVEF Changes After TAVR
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Relationship between the maximal increase in CK-MB levels and the changes in LVEF after
TAVR. LVEF ¼ left ventricular ejection fraction; other abbreviations as in Figure 1.
FIGURE 6 Absolute Change (D) in LVEF According to the CK-MB Peak After TAVR
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2085Transcatheter Aortic Valve Replacement) trial (19),
patients receiving a self-expandable valve exhibited
longer procedural times, received a higher volume of
contrast agent and had an increased incidence of
valve embolization/need for a second valve compared
to the balloon-expandable group. This may partially
explain the differences in myocardial injury between
valve types, but given the non-randomized nature of
the study, future studies are warranted to conﬁrm
and better understand the mechanisms associated
with these results. Importantly, no differences be-
tween valve types were observed in those patients
with the highest (>5-fold) increase in CK-MB levels.
CLINICAL IMPACT OF PERI-PROCEDURAL TAVR-RELATED
MYOCARDIAL INJURY. The occurrence and degree of
myocardial injury after cardiac surgery and percuta-
neous coronary intervention have been associated
with poorer short and mid-term clinical outcomes
(7,20). Importantly, the degree of CK-MB increase and
the associated worse outcomes formed the basis for
deﬁning the occurrence of clinically relevant
myocardial infarction after such procedures (7). This
is of major clinical relevance considering the changes
in the acute and late management of such patients,
compared with those without periprocedural
myocardial infarction.
Following a similar theme, previous studies in the
TAVR ﬁeld have demonstrated increased short- and
mid-term mortality to be associated with greater
rise in biomarkers of myocardial injury after the
procedure (2,4,6,21,22). However the limited number
of patients/events in most studies precluded a
formal validation of a threshold of biomarker eleva-
tion representing a “clinically relevant” myocardial
infarction after TAVR. Our study conﬁrms the major
impact of myocardial injury as determined by CK-MB
rise post TAVR on 30-day and 1-year overall mortality
and extends previous observations by showing an
increased risk of late (>1-year) overall and cardiac
mortality in relationship to higher degrees
of myocardial injury. In accordance with previous
studies (22), any increase in CK-MB values associated
with poorer outcomes, with an apparent stepwise
increase in late mortality according to the various
degrees of CK-MB elevation after TAVR. Interest-
ingly, according to the VARC-2 criteria for deﬁning
clinically relevant myocardial infarction (6), a >5-fold
increase in CK-MB threshold was associated with a
higher mortality rate. This suggests that patients with
greater degrees of myocardial injury could poten-
tially beneﬁt from both a closer clinical follow-up as
well as medications for preventing adverse
LV remodeling in such cases (i.e., angiotensin-
converting enzyme inhibitors, angiotensin-receptorblockers, beta-blockers, or spironolactone). How-
ever, this needs further prospective evaluation in
future studies. Interestingly, the correlation between
a greater increase in CK-MB levels and mortality
post TAVR was apparent in the TF but not in the
TA approach cohort, although the relatively low
number of patients in the TA group may partially
explain such results.
CENTRAL ILLUSTRATION Incidence, Predictors, and Cumulative Mortality According to Various Degrees of Increase in
CK-MB Levels After TAVR
Ribeiro, H.B. et al. J Am Coll Cardiol. 2015; 66(19):2075–88.
Percent of patients with each fold of increase in creatinine kinase-myocardial band (CK-MB) levels, for the overall population and according to approach,
including its independent predictors and the ensuing cumulative mortality for the entire population and the nontransapical approach group.
TAVR ¼ transcatheter aortic valve replacement.
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2086Greater elevations in CK-MB levels were also
correlated with impaired LV function at mid-term
follow-up, which is consistent with previous studies
(2,12,13). Therefore, it is important to keep in mind
that strategies for reducing the ensuing myocardial
injury in TAVR patients, especially in those patients
with impaired baseline LVEF pre-TAVR, are of utmost
importance (13,23). Accordingly, it has been sug-
gested that in those patients with low LVEF deemed
unsuitable for TF-TAVR, other alternative approaches
such as transaortic, subclavian, or transcarotid ap-
proaches would be preferable to the TA approach.
Improvements in the design of the TA delivery sys-
tems for minimizing apical trauma should also beencouraged (13,15). Additionally, future enhance-
ments to the TF delivery system with more easily
used transcatheter valves, may facilitate deployment
with shorter rapid-pacing runs and lower ischemic
times (24).
STUDY LIMITATIONS. Although the present analysis
includes a large cohort of TAVR patients with sys-
tematic cardiac biomarker evaluation, the patients
were however not randomized according to approach
and valve type. Consequently, the multivariate anal-
ysis may not have accounted for the unmeasured
between-group confounders unduly inﬂuencing
study conclusions. The participating centers used
different assays for measuring CK-MB levels and this
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Evidence of
myocardial injury emerges commonly in patients after TAVR.
Predictors of injury include a transapical approach, operator/
center early experience, procedural complications such as
major bleeding, device embolism, and need for a second
prosthesis or surgery. More severe myocardial injury (particu-
larly CK-MB >5 times the upper limit or normal) is associated
with late LV dysfunction and increased acute and late
mortality.
TRANSLATIONAL OUTLOOK: Future studies are needed to
identify patients before TAVR who are at greatest risk of peri-
procedural myocardial injury and to develop management stra-
tegies to minimize its adverse impact on clinical outcomes.
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2087intercenter variability may have inﬂuenced the re-
sults. This was partially offset by the use of a relative
increase in CK-MB levels with respect to the upper
normal limits (fold or increase) as recommended by
VARC-2 (6). Also, a hierarchical analysis was per-
formed to account for between-center/country vari-
ance. Echocardiographic data were based on each
site report, and no central echocardiographic core
laboratory analysis was available. All centers were
encouraged to calculate LVEF by using the Simpson
method in order to improve accuracy and reduce
variability (25). Although data on previous coronary
artery disease and need for revascularization was
complete, no data were available on the completeness
of coronary revascularization before TAVR. The in-
ﬂuence of this factor on myocardial injury post TAVR
will need to be determined in future studies. Addi-
tionally, one might argue that cardiac troponins
should be the preferred biomarkers for the diagnosis
of myocardial injury because of their higher sensi-
tivity and speciﬁcity than CK-MB levels (8,26,27).
Nonetheless, acute and chronic comorbidities
frequently lead to small elevations in troponin levels
at baseline, that together with the recently developed
ultra and highly-sensitive assays, along with its
diverse analytical sensitivity (28), will likely lead to a
myriad of challenges to deﬁne a precise cutoff of
myocardial injury in such patients according to
troponin (26). Finally, the early mortality rate
observed in our study was relatively high compared
to more recent TAVR series. Future studies in the
context of TAVR, with the systematic measurement of
CK-MB and troponin, are necessary to further eval-
uate its prognostic signiﬁcance and conﬁrm the most
appropriate cut-off to predict worse clinical out-
comes, also with valve types other than the balloon-
expandable and self-expandable systems, including
the latest generation of transcatheter valves.
CONCLUSIONS
Myocardial injury as determined by CK-MB rise is
frequent among TAVR patients, especially with TA-
TAVR, and in those patients suffering from major
procedural complications. These results support the
use of alternative approaches to TA, particularly insome patients at risk, like those with impaired
LVEF. Also, reducing the size of transfemoral
sheaths and increasing heart team experience and
the retrievability/repositionability properties of
most of the more recent generation transcatheter
valves should be associated with a signiﬁcant
reduction in bleeding and malpositioning/emboli-
zation complications, which may translate into a
reduction in the degree of myocardial injury post
TAVR. This, however, will need to be determined in
future studies. A higher degree of myocardial injury
was associated with poorer acute and late out-
comes. Although any increase in CK-MB levels as-
sociates with poorer clinical outcomes, there is a
stepwise increase in late mortality according to the
various degrees of CK-MB elevation. In line with the
VARC-2 deﬁnition for clinically relevant myocardial
infarction post TAVR, a CK-MB rise >5-fold the
upper normal limits related with incremental mor-
tality rates, although the best cutoff for predicting
mortality should be conﬁrmed in future studies.
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